Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts

Anti-Cancer Drugs

Volumn 20, Issue 10, 2009, Pages 932-940

  Némati, Fariba ^a   Bras Gonçalves, Rui ^e   Fontaine, Jean Jacques ^f   De Pinieux, Gonzague ^g   De Cremoux, Patricia ^b   Chapelier, Alain ^h   Daniel, Catherine ^a   Laurent Puig, Pierre ^d   Livartowski, Alain ^a   Judde, Jean Gabriel ⁱ   Bordier, Vincent ^c   Poupon, Marie France ^a   Decaudin, Didier ^a  

^a Department of Translational Research ^*  (France)

^b Department of Tumor Biology

^c INSTITUT CURIE   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^f ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^g SERVICE DE DERMATOLOGIE   (France)

^h FOCH HOSPITAL   (France)

ⁱ Suresnes and KXenTech   (France)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Drug resistance; Gemcitabine; Gene expression; Non small cell lung cancer; Vinorelbine; Xenograft model

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

AGED; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73349101817     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833009cc     Document Type: Article

References (26)

1. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American Society of Clinical Oncology treatment of unresectable non-smallcell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-353.
2. Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:277S-289S. (Pubitemid 47502813)
3. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Addition of platinum compounds to a new agent in patients with advanced non-smallcell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 2004; 15:1782-1789.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98. (Pubitemid 34438899)
5. Magne N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ('Iressa'). Br J Cancer 2002; 86:1518-1523.
6. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3:RESEARCH0034.
7. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003; 22:9075-9086.
8. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003; 104:121-129.
9. Ko YH, Lee MA, Hong YS, Lee KS, Park HJ, Yoo Ie R, et al. Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients. Korean J Intern Med 2007; 22:178-185.
10. Mattson K, Bosquee L, Dabouis G, Le Groumellec A, Pujol JL, Marien S, et al. Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice. Lung Cancer 2000; 29:205-216.
11. Hainsworth JD, Spigel DR, Farley C, Shipley DL, Bearden JD, Gandhi J, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007; 110:2027-2034.
12. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, DeMarinis F, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:3390-3399. (Pubitemid 30821916)
13. Kocak M, Mayadagli A, Ozkan A, Parlak C, Demir O, Marti A, et al. Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience. J Buon 2007; 12:471-476.
14. Katakami N, Takiguchi Y, Yoshimori K, Isobe H, Bessho A, Yoshimura A, et al. Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol 2006; 1:447-453.
15. Syrigos KN, Karapanagiotou E, Charpidou A, Dilana K, Dannos I, Dionellis G, et al. Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study. J Chemother 2007; 19:438-443. (Pubitemid 47236524)
16. Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer 2008; 59:57-63.
17. Han K, Cao W, Che J, Bo S, Guo X, Huang G, et al. First line chemotherapy with weekly docetaxel and cisplatin in elderly patients with advanced nonsmall cell lung cancer: a multicenter phase II study. J Thorac Oncol 2009; 4:512-517.
18. Georgoulias V, Scagliotti G, Miller V, Eckardt J, Douillard JY, Manegold C. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. Semin Oncol 2001; 28:15-21.
19. Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000; 18:2301-2308.
20. Deloia JA, Zamboni WC, Jones JM, Strychor S, Kelley JL, Gallion HH. Expression and activity of taxane-metobolizing enzymes in ovarian tumors. Gynecol Oncol 2008; 108:355-360.
21. Park JS, Yamamoto W, Sekikawa T, Matsukawa M, Okamoto R, Sasaki M, et al. Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int J Oncol 2002; 20:333-338.
22. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cisdiamminedichloroplatinum(II). Cancer Res 1998; 58:1120-1123.
23. Nagatani G, Nomoto M, Takano H, Ise T, Kato K, Imamura T, et al. Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells. Cancer Res 2001; 61:1592-1597.
24. Schettino C, Bareschino MA, Maione P, Rossi A, Ciardiello F, Gridelli C. The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. Curr Genomics 2008; 9:252-262.
25. Hayashi Y, Kuriyama H, Umezu H, Tanaka J, Yoshimasu T, Furukawa T, et al. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med 2009; 48:203-208.
26. Shalli K, Brown I, Heys SD, Schofield AC. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 2005; 19:1299-1301.